Dragon Pharma Cheque Drops

IDENTITYCompoundMibolerone
BrandDragon Pharma
Strength250 mcg/tab
FormOral Tablet
ClassOral Anabolic Steroid

PHARMACOLOGYCompound Type19-Nor Androgen Derivative
AdministrationOral (PO)
Androgenic ActivityVery High
Anabolic ActivityHigh
AromatizationMinimal

SAFETY PROFILEHPTA SuppressionVery High
Liver ImpactPotential Oral Steroid Stress
Lipid EffectsPossible Adverse Changes
Estrogenic ActivityLow
PCTRequired

STORAGE & PACKAGEBrandDragon Pharma
Package100 Tablets
StorageBelow 25°C
ProtectionDry Place / Light Protection
Formulation250 mcg Tablets

BODYBUILDING USAGE Usage Short-term pre-training androgenic application
Administration Oral tablet taken before training
Typical Amount100–250 mcg/day
Maximum ExposureShort duration only
Duration Usually measured in days, not weeks

DOSING INFORMATIONBeginner Profile100 mcg/day
Intermediate Profile100–250 mcg/day
Advanced Profile250 mcg/day
Weekly Equivalent0.7–1.75 mg/week
Administration Oral use, usually pre-workout timing

USAGE PROFILEOnsetRapid androgen activity
Active PeriodShort acting compound
Typical TimeSeveral hours after administration
DurationShort-term application
Purpose Acute strength and aggression effects

RECOVERY & DISCONTINUATIONSuppression Strong testosterone suppression possible
Recovery StartAfter clearance and medical evaluation
SERM SupportCommon recovery approach
DurationOften several weeks
Monitoring Hormonal blood testing recommended

STACK COMPATIBILITYBulking Not commonly used for long bulking phases
Strength FocusHigh androgenic profile
CuttingLimited practical application
SupportBlood pressure and lipid monitoring
Combination Requires advanced pharmacological knowledge

MECHANISM OF ACTIONTargetAndrogen Receptor
ActionModulates androgen signaling
ProteinSupports anabolic pathways
NitrogenPositive retention potential
HormoneSynthetic androgen derivative

PHARMACOKINETICSRouteOral absorption
MetabolismHepatic metabolism
Half-lifeLimited clinical data available
ReleaseRapid oral profile
DurationShort acting

CONTRAINDICATIONSLiver DiseaseAvoid use
CardiovascularRisk assessment required
LipidsMonitor cholesterol profile
HormonalSuppression risk
PregnancyContraindicated

CHEMICAL PROFILESubstanceMibolerone
FormulaC20H26O2
Molecular Weight298.42 g/mol
CAS3704-09-4
Category19-Nor Testosterone Derivative

OVERVIEW

Dragon Pharma Cheque Drops contains Mibolerone, a highly potent oral androgenic anabolic steroid belonging to the 19-nor steroid family. Mibolerone was originally developed as a veterinary pharmaceutical compound and is recognized for its extremely strong androgen receptor activity.

BENEFITS

Very strong androgen receptor activation
Rapid strength-supporting effects
High androgenic profile
Short acting oral administration
Minimal estrogen conversion
Potential increase in training intensity
Compact tablet administration

POTENTIAL SIDE EFFECTS

Strong natural testosterone suppression
Negative cholesterol changes
Possible blood pressure increase
Androgenic skin effects
Acne and oily skin
Mood alteration potential
Liver enzyme elevation risk

PERFORMANCE PROFILE

Androgen Activity

98%

Strength

90%

Muscle Support

82%

Recovery

75%

Estrogenic Activity

10%

WHY CHOOSE DRAGON PHARMA

Dragon Pharma is recognized in bodybuilding communities as a pharmaceutical-style brand producing a wide range of performance-oriented products. Cheque Drops is presented as a high-potency Mibolerone formulation with a standardized tablet strength of 250 mcg per tablet.

Product quality, accurate labeling, manufacturing standards and responsible handling are important considerations when evaluating any pharmaceutical compound. Independent verification and proper storage practices remain essential factors for maintaining product integrity.

CONCLUSION

Dragon Pharma Cheque Drops provides Mibolerone in a concentrated oral tablet format. Mibolerone is classified as an extremely potent androgenic anabolic steroid with rapid pharmacological activity and a strong interaction with androgen receptors.

Compared with traditional anabolic steroids, Mibolerone has a unique profile characterized by very high androgenic potency, short-term activity and significant hormonal suppression potential. It is not considered a general-purpose anabolic compound and requires careful understanding of pharmacology, health monitoring and risk factors.

Athletes researching Mibolerone should consider laboratory monitoring, cardiovascular health markers, lipid profile changes and endocrine recovery before evaluating any application of this compound.

Within bodybuilding discussions, Mibolerone is known for its rapid onset profile and intense androgenic characteristics. Due to its potency, short duration of use and significant suppression potential, it is considered an advanced-level compound rather than a conventional anabolic base product.

Scientific information regarding Mibolerone pharmacology can be reviewed through resources such as PubMed research and DrugBank pharmacological databases.

DISCLAIMER

This information is provided for educational and scientific purposes only. It does not represent medical advice, prescribing guidance or encouragement of non-medical anabolic steroid use. Mibolerone may present significant health risks and should only be evaluated within appropriate medical and legal frameworks.